Coronavirus disease 2019 (COVID-19) is an infectious disease of the respiratory system that caused a pandemic in 2020. There is still not any effective special treatment to cure it. Drug repositioning is used to find an effective drug for curing new diseases by finding new efficacy of registered drug. The new efficacy can be conducted by elaborating the interactions between compounds and proteins (DTI). Deep Semi-Supervised Learning (DSSL) is used to overcome the lack of DTI information. DSSL utilizes unsupervised learning algorithms such as Stacked Auto Encoder (SAE) as pre-training for initializing weights on the Deep Neural Network (DNN). This study uses DSSL with a feature-based chemogenomics approach on the data resulted from the exploration of potential anti-coronavirus treatment. This study finds that the use of fingerprints for compound features and Dipeptide Composition (DC) for protein features gives the best results on accuracy (0.94), recall (0.83), precision (0.817), F-measure (0.822), and AUROC (0.97). From the test data predictions, 1766 and 929 positive interactions are found on the test data and herbal compounds, respectively. Keywords-coronavirus disease 2019, drug repositioning, deep semi-supervised learning, stacked autoencoder, deep neural network
II. DEEP SEMI-SUPERVISED LEARNING FOR DTIResearch on drug repositioning is based on the fact that most drug compounds can activate or inhibit the biological functions of the target protein. This creates the needs to develop a DTI identification system [11]. DTI identification